TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Serum 25(OH) D level >30 ng/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline consistent condom use
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Ventilatory Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Shoulder and Elbow Surgeons (ASES) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Structural and Functional Changes in Brain Structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of cases of acute lung injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of DA-3803 (r-hCG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of DA-3803 (r-hCG)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in patient's assessment of pain (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overall pain and function (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically significant improvement or worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in pain due to OA of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of episodes of cerebral bleeding or clinically significant upper-gastro-intestinal bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Number of episodes of MRI-proven brain infarction or death
Endpoint domain: Mortality/survival
Primary endpoint: Breast Cancer Screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to first adjuvant chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Molecular genetic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Parasitological Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time for Parasite Count to Fall by 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time for Parasite Count to Fall by 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Nasopharyngeal SARS-CoV-2 Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Oropharyngeal SARS-CoV-2 Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Saliva SARS-CoV-2 Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Catabolic Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants delivering by NVD without instrumental intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients having at least one adverse event related to DAV132 and/or fluoroquinolones
Endpoint domain: Adverse events/effects
Primary endpoint: Bone Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recurrent AHRE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success Rate Based on Pulp Vitality Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Assessment Using Visual Analog Pain Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee injury and Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ECG's
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Extrinsic Stains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of suicide
Endpoint domain: Mortality/survival
Primary endpoint: Overall Improvement for the Target Lesion on the Scalp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Treatment efficiency in repairing the pectus carinatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Treatment safety
Endpoint domain: Adverse events/effects
Primary endpoint: Albumin to Creatinine Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of subclinical proximal tubular abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Economic consequences of antibiotic selection
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical consequences of antibiotic selection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anxiety and depression level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Generalised Anxiety Disorder Assessment (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient Health Questionnaire (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tmax - Time to Reach Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t - Area Under the Plasma Concentration-time Curve From Time 0 to Last Observed Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of b-hexosaminidase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokines levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cognition on the RBANS Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vegetable Intake Carotenoid Scores at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vegetable Intake Carotenoid Scores at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Reported Vegetable Intake at 3 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-Reported Vegetable Intake at 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Redeemed Any Farmers' Market Nutrition Program (FMNP) Vouchers at 6 Months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death
Endpoint domain: Mortality/survival
Primary endpoint: corrected flow time (FTc) in carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 11C-PBR28 binding (standardized uptake value ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of multiple symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of symptoms on daily functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Apparent total plasma clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of ILD cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive Haemagglutination Inhibition Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sustained Viral Response (SVR) at Follow-up Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Urticaria Activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change from baseline in average pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five Minute Speech Sample (FMSS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Modified Camberwell Family Interview (CFI)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Preterm labor incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Composite Responders Based on Improvements in Daily Worst Abdominal Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Composite Responders Based on Improvements in Daily Stool Consistency Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: associated complications of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: subjective sequelae score of lower extremity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: subjective sequelae score of upper extremity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: relevant restricted range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in foot print with pedography (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in sitting diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Experiencing a Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: FEV1/FVC change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) score change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 75% reduction in GERD HRQL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Outcome Assessed at Test of Cure Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Functional Performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Quantification of 18F-PF-06445974 binding in brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline to Day 5 in plasma HCV ribonucleic acid (RNA) in GT1 participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum reduction from baseline through Day 5 in HCV ribonucleic acid (RNA) in GT3 participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants experiencing at least one adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of attached gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Melasma Severity Rating Scale Score to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Overall Hyperpigmentation Scale Score to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Melasma Area and Severity Index (MASI) Score to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Luteal Montgomery-Asberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of Grade 3 or Higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Wheelchair User's Shoulder Pain Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in the mean monthly number of migraine attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing at Least One Dose-Limiting Toxicity (DLT) Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery 15
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety and toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of pCR at Primary Site and Nodal Sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Parasite clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: White Matter Microstructural Maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State of hyperfibrinolysis on hospital admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adenosine induced vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with LCOS
Endpoint domain: Mortality/survival
Primary endpoint: Pregnancy Reported as Pearl Index
Endpoint domain: Mortality/survival
Primary endpoint: MRC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxycodone Oral Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood flow quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: NHLBI recommended controller medications usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Canadian Occupational Performance Measure (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Children´s hand-use Experience Questionnaire (CHEQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PV Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PV Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LS-MRE for Sub-Study I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: True Diffusion Parameter (D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LS-MRE Fibrosis State for Sub Study II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LS-TE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain sensitivity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ5D-5L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: posturography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed up and Go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of endoleak type II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Сardiovascular Death
Endpoint domain: Mortality/survival
Primary endpoint: Cardiovascular Hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sleep dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Anti-Mullerian Hormone levels variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum Plasma Concentration of BIA 2-005 (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Plasma Concentration of BIA 2-005 (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' preferences in renal cell carcinoma
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oncologists' preferences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent reduction in left ventricular end systolic volume (LVESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptoms due to FPIES
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular global longitudinal strain (GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global score on the Modified Fatigue Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Physical and Cognitive Performance Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Families With a Fire Escape Plan
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Decrease in Pain and Symptoms Caused by Hypertonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stabilisation of vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extracellular Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracellular Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Body Fluid Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid Overload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTS severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with IMCI guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Urinary C-peptide Creatinine Ratio (UCPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: perforation rate of the subantral membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with Treatment Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Intensity of an adverse event graded using the NCI CTCAE version 4.03
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration of BAY 1841788 characterized by Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who died during the study
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of microvascular complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of patients correctly classified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in curriculum-based measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Dose distribution on the CTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dose distribution on the OAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total Cough Count Over 8 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Cough Count Excluding Transient Coughs Over 8 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Schimer's Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oil stained area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Overall Improvement From Baseline in Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Sustained Viral Response at 12 Weeks Post Treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in renal function (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of participants readmitted to the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total Body Muscle Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants achieving PSA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in liver stiffness measured by transient elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in indocyanine green excretion test using plasma disappearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in indocyanine green excretion test using plasma retention rate at 15 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving of opiates
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of lofexidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes